Monday, November 9th, 2009 - UniQuest Pty Limited
An innovative prostrate cancer treatment device developed by University of Wollongong (UOW) researchers has enhanced the Prostate Immobilizer Balloon System launched by US Texas company, RadiaDyne, at the American Society for Therapeutic Radiology and Oncology (ASTRO) convention in Chicago earlier this week.

The technologically advanced ‘Prostate Immobilizer Balloon System’, which supports adaptive radiation therapy for prostate cancer patients, incorporates sensors developed by the University’s Centre for Medical Radiation Physics (CMRP), under the directorship of Professor Anatoly Rozenfeld.

UOW licensed the technology exclusively to RadiaDyne for its Prostate Immobiliser System, with the assistance of commercialisation partner, UniQuest. The patent has been registered internationally, and it is anticipated that the new version of the system with the novel sensor will be available for commercial sales in the United States within six months, pending regulatory clearance from the Food and Drug Administration (FDA).

According to Manager of Innovation and Commercialisation Tony Enright, the Moskin Dosimetry Sensor Technology detects and measures in real-time the radiation exposure immediately adjacent to the rectal wall when a patient is undergoing treatment for prostate cancer.

“The rectal wall is an area particularly susceptible to radiation exposure. For patients undergoing adaptive radiation therapy, this advance in the technology means greater protection from potential complications that are known to occur,” Mr Enright said.

“Launching this innovation into the market via RadiaDyne’s system is going to make a real difference to prostate cancer patients in the near future.”

For more information on the system using UOW’s Moskin Dosimetry Sensor Technology, visit the RadiaDyne website: http://www.radiadyne.com

Contact Profile

UniQuest Pty Limited


Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1,500+ patents it has created over 60 companies, and since 2000 UniQuest and its start-ups have raised more than $400 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at $3 billion. UniQuest now commercialises innovations developed at The University of Queensland and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health. UniQuest also provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to meet the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services each year.

UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank, UniQuest has developed and implemented more than 400 projects in 46 countries throughout the Pacific, South-East Asia, the Indian sub-continent and Africa.


Leanne Wyvill
P: +61 7 3365 4037
M: +61 0 409767199
W: www.uniquest.com.au

UniQuest


Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. It has created more than 60 companies, and since 2000 UniQuest and its start-ups have raised a quarter of a billion dollars to take UQ technologies to market. Sales of products using UQ technology and licensed by UniQuest are now running at $5.2 billion per year. UniQuest also commercialises innovations developed at the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, the Mater Medical Research Institute and two ARC Centres of Excellence. As well, UniQuest can access thousands of researchers and experts and tailor a consulting or project R&D solution to meet the needs of industry and government. UniQuest is also a leading Australasian provider of international development assistance projects. Working with agencies such as AusAID, NZAID, the Asian Development Bank, and the World Bank, UniQuest has developed and implemented projects in 45 countries throughout Pacific, South-East Asia, the Indian sub-continent and Africa. For more information about UniQuest, please visit www.uniquest.com.au.
Tony Enright
P: +61 2 4221 4129
W: www.radiadyne.com

Keywords

This Australian university-developed technology will offer better patient outcomes in the future.

Categories

Sharing

More Formats